Inxmed (shanghai) Co., Ltd.
Clinical trials sponsored by Inxmed (shanghai) Co., Ltd., explained in plain language.
-
New combo targets tough cancers: hope for KRASG12D patients
Disease control Recruiting nowThis study tests two experimental drugs, IN10018 and RNK08954, together in people with advanced solid tumors that have a specific KRASG12D mutation. The goal is to find the best dose and see if the combination can shrink tumors. About 92 adults with locally advanced or metastatic…
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New drug duo aims to outshine standard therapy for KRAS G12C lung cancer
Disease control Recruiting nowThis study tests whether a combination of two experimental drugs (IN10018 and D-1553) works better than the usual treatment for people with a specific type of advanced lung cancer called KRAS G12C non-small cell lung cancer. About 400 adults who have not had prior treatment for t…
Phase: PHASE3 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New hope for ovarian cancer: drug combo targets resistant tumors
Disease control Recruiting nowThis study tests a new drug called IN10018 combined with standard chemotherapy in people with a tough-to-treat type of ovarian cancer that no longer responds to platinum-based drugs. About 150 adults will take part to see if the combination is safe and shrinks tumors. The goal is…
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 08, 2026 13:05 UTC